vs
Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
BIOMARIN PHARMACEUTICAL INC is the larger business by last-quarter revenue ($874.6M vs $853.7M, roughly 1.0× Primerica, Inc.). Primerica, Inc. runs the higher net margin — 23.1% vs -5.3%, a 28.4% gap on every dollar of revenue. On growth, BIOMARIN PHARMACEUTICAL INC posted the faster year-over-year revenue change (17.0% vs 11.0%). Over the past eight quarters, BIOMARIN PHARMACEUTICAL INC's revenue compounded faster (16.1% CAGR vs 7.2%).
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
BMRN vs PRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $874.6M | $853.7M |
| Net Profit | $-46.6M | $197.0M |
| Gross Margin | 68.5% | — |
| Operating Margin | -5.1% | 28.9% |
| Net Margin | -5.3% | 23.1% |
| Revenue YoY | 17.0% | 11.0% |
| Net Profit YoY | -137.3% | 17.9% |
| EPS (diluted) | $-0.22 | $6.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $874.6M | $853.7M | ||
| Q3 25 | $776.1M | $839.9M | ||
| Q2 25 | $825.4M | $793.3M | ||
| Q1 25 | $745.1M | $804.8M | ||
| Q4 24 | $747.3M | $768.8M | ||
| Q3 24 | $745.7M | $774.1M | ||
| Q2 24 | $712.0M | $803.4M | ||
| Q1 24 | $648.8M | $742.8M |
| Q4 25 | $-46.6M | $197.0M | ||
| Q3 25 | $-30.7M | $206.8M | ||
| Q2 25 | $240.5M | $178.3M | ||
| Q1 25 | $185.7M | $169.1M | ||
| Q4 24 | $124.9M | $167.1M | ||
| Q3 24 | $106.1M | $164.4M | ||
| Q2 24 | $107.2M | $1.2M | ||
| Q1 24 | $88.7M | $137.9M |
| Q4 25 | 68.5% | — | ||
| Q3 25 | 82.0% | — | ||
| Q2 25 | 81.8% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 74.7% | — | ||
| Q2 24 | 81.7% | 98.0% | ||
| Q1 24 | 80.7% | 98.2% |
| Q4 25 | -5.1% | 28.9% | ||
| Q3 25 | -6.0% | 32.3% | ||
| Q2 25 | 33.5% | 29.6% | ||
| Q1 25 | 30.0% | 27.5% | ||
| Q4 24 | 21.6% | 64.7% | ||
| Q3 24 | 15.3% | 32.9% | ||
| Q2 24 | 16.9% | 1.0% | ||
| Q1 24 | 13.6% | 24.1% |
| Q4 25 | -5.3% | 23.1% | ||
| Q3 25 | -4.0% | 24.6% | ||
| Q2 25 | 29.1% | 22.5% | ||
| Q1 25 | 24.9% | 21.0% | ||
| Q4 24 | 16.7% | 21.7% | ||
| Q3 24 | 14.2% | 21.2% | ||
| Q2 24 | 15.1% | 0.1% | ||
| Q1 24 | 13.7% | 18.6% |
| Q4 25 | $-0.22 | $6.11 | ||
| Q3 25 | $-0.16 | $6.35 | ||
| Q2 25 | $1.23 | $5.40 | ||
| Q1 25 | $0.95 | $5.05 | ||
| Q4 24 | $0.65 | $4.92 | ||
| Q3 24 | $0.55 | $4.83 | ||
| Q2 24 | $0.55 | $0.03 | ||
| Q1 24 | $0.46 | $3.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $756.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.1B | $2.4B |
| Total Assets | $7.6B | $15.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $756.2M | ||
| Q3 25 | $1.3B | $644.9M | ||
| Q2 25 | $1.2B | $621.2M | ||
| Q1 25 | $1.0B | $625.1M | ||
| Q4 24 | $942.8M | $687.8M | ||
| Q3 24 | $675.4M | $550.1M | ||
| Q2 24 | $972.1M | $627.3M | ||
| Q1 24 | $747.0M | $593.4M |
| Q4 25 | $6.1B | $2.4B | ||
| Q3 25 | $6.1B | $2.3B | ||
| Q2 25 | $6.0B | $2.3B | ||
| Q1 25 | $5.8B | $2.3B | ||
| Q4 24 | $5.7B | $2.3B | ||
| Q3 24 | $5.4B | $1.9B | ||
| Q2 24 | $5.3B | $2.1B | ||
| Q1 24 | $5.1B | $2.2B |
| Q4 25 | $7.6B | $15.0B | ||
| Q3 25 | $7.6B | $14.8B | ||
| Q2 25 | $7.5B | $14.8B | ||
| Q1 25 | $7.1B | $14.6B | ||
| Q4 24 | $7.0B | $14.6B | ||
| Q3 24 | $6.9B | $14.8B | ||
| Q2 24 | $7.1B | $14.6B | ||
| Q1 24 | $6.9B | $14.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.6M | $338.2M |
| Free Cash FlowOCF − Capex | $58.9M | — |
| FCF MarginFCF / Revenue | 6.7% | — |
| Capex IntensityCapex / Revenue | 4.7% | — |
| Cash ConversionOCF / Net Profit | — | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $725.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.6M | $338.2M | ||
| Q3 25 | $368.7M | $202.9M | ||
| Q2 25 | $185.3M | $162.6M | ||
| Q1 25 | $174.4M | $197.5M | ||
| Q4 24 | $185.6M | $270.6M | ||
| Q3 24 | $221.5M | $207.3M | ||
| Q2 24 | $118.8M | $173.3M | ||
| Q1 24 | $47.0M | $210.9M |
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $168.2M | — | ||
| Q1 25 | $157.6M | — | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $203.0M | — | ||
| Q2 24 | $97.4M | — | ||
| Q1 24 | $20.9M | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.2% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 4.0% | — |
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | 0.77× | 0.91× | ||
| Q1 25 | 0.94× | 1.17× | ||
| Q4 24 | 1.49× | 1.62× | ||
| Q3 24 | 2.09× | 1.26× | ||
| Q2 24 | 1.11× | 147.98× | ||
| Q1 24 | 0.53× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
